New First-Line Standard of Care for Esophageal Cancer? New First-Line Standard of Care for Esophageal Cancer?
Pembrolizumab plus chemotherapy should be a new standard of care for first-line treatment, say researchers. Patients with squamous cell carcinomas and higher levels of PD-L1 benefited most.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 23, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
A Breath Test to Diagnose Head and Neck Cancer A Breath Test to Diagnose Head and Neck Cancer
Breath analysis for non-invasive diagnosis of early-stage head and neck squamous cell carcinoma appears to be practical and accurate.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 22, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
What Are Systemic Disease Causes of Oral Ulcers?
Discussion
Oral ulcers are common problems seen by dentists but pediatricians also see them. Usually families have are concerned because they are painful and acute. Ulcers are sometime noticed by the physician and not the family as in the case of herpangina or hand-foot and mouth disease. Chronic or recurrent ulcerations present less commonly and therefore it may be more difficult to determine their etiology. Many of the systemic disease causes of oral ulcers are overall infrequent and/or not common in the pediatric age range.
Ulcers can be classified in several ways but acute ulcers are usually painful and last less tha...
Source: PediatricEducation.org - September 21, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Robotic surgery may improve outcomes in mouth and throat cancer
(Cedars-Sinai Medical Center) Robotic surgery for patients with early stage, oropharyngeal squamous cell cancer is associated with improved health outcomes, including better long-term survival, according to a Cedars-Sinai study published Thursday in JAMA Oncology. Oropharyngeal cancer occurs in the back of the throat and includes the base of the tongue and tonsils. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 20, 2020 Category: Cancer & Oncology Source Type: news
Researchers ID new target in drive to improve immunotherapy for cancer
FINDINGSResearchers at the UCLA Jonsson Comprehensive Cancer Center and UCLA School of Dentistry have identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma, the most common type of head and neck cancer.A study in mice found that using an anti-PD1 immunotherapy drug in combination with PTC209, an inhibitor that targets the protein BMI1, successfully stopped the growth and spread of the cancer, prevented reoccurrences and eliminated cancer stem cells. This is the first preclinical study to provide evidence that targeting BMI1 proteins enhances immunotherapy and eliminates ca...
Source: UCLA Newsroom: Health Sciences - July 21, 2020 Category: Universities & Medical Training Source Type: news
Researchers ID new target in drive to improve immunotherapy for cancer
(University of California - Los Angeles Health Sciences) UCLA researchers have identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma, the most common type of head and neck cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 21, 2020 Category: Cancer & Oncology Source Type: news
Tumor-initiating cells establish an IL-33-TGF-{beta} niche signaling loop to promote cancer progression
Targeting the cross-talk between tumor-initiating cells (TICs) and the niche microenvironment is an attractive avenue for cancer therapy. We show here, using a mouse model of squamous cell carcinoma, that TICs play a crucial role in creating a niche microenvironment that is required for tumor progression and drug resistance. Antioxidant activity in TICs, mediated by the transcription factor NRF2, facilitates the release of a nuclear cytokine, interleukin-33 (IL-33). This cytokine promotes differentiation of macrophages that express the high-affinity immunoglobulin E receptor FcRIα and are in close proximity to TICs. ...
Source: ScienceNOW - July 15, 2020 Category: Science Authors: Taniguchi, S., Elhance, A., Van Duzer, A., Kumar, S., Leitenberger, J. J., Oshimori, N. Tags: Cell Biology, Medicine, Diseases, Online Only r-articles Source Type: news
Oncotarget: Tumor markers for carcinoma identified by imaging mass spectrometry
(Impact Journals LLC) Volume 11, Issue 28 of Oncotarget features 'Lipid and protein tumor markers for head and neck squamous cell carcinoma identified by imaging mass spectrometry' by Schmidt et, al. which reported that the authors used MALDI imaging mass spectrometry and immunohistochemistry to seek tumor-specific expression of proteins and lipids in HNSCC samples. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 14, 2020 Category: International Medicine & Public Health Source Type: news
A 3D biofabricated cutaneous squamous cell carcinoma tissue model
(Impact Journals LLC) The cover for issue 27 of Oncotarget features Figure 4, " (A) Bimodal imaging examples of control and treated tumors (red) before and after the treatment period, " by Browning, et al. and reported that the authors developed a 3-dimensional bioprinted skin model of cutaneous squamous cell carcinoma (cSCC) tumors together with a microscopy assay to test chemotherapeutic effects in tissue. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2020 Category: Cancer & Oncology Source Type: news
Roche improves speed and accuracy of non-small cell lung cancer diagnosis with launch of automated digital pathology algorithm
Basel, June 26, 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE-IVD launch of its automated digital pathology algorithm, the uPath PD-L1 (SP263) image analysis for non-small cell lung cancer (NSCLC). The algorithm provides pathologists with automated assessments of scanned slide images that are objective and reproducible and have the potential to aid diagnosis and, ultimately, targeted treatment options for patients. Validated on the VENTANA PD-L1 (SP263) Assay, the algorithm is ready-to-use and integrated within the Roche uPath enterprise software, a universal digital platform fo...
Source: Roche Investor Update - June 26, 2020 Category: Pharmaceuticals Source Type: news
Roche improves speed and accuracy of non-small cell lung cancer diagnosis with launch of automated digital pathology algorithm
Basel, June 26, 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE-IVD launch of its automated digital pathology algorithm, the uPath PD-L1 (SP263) image analysis for non-small cell lung cancer (NSCLC). The algorithm provides pathologists with automated assessments of scanned slide images that are objective and reproducible and have the potential to aid diagnosis and, ultimately, targeted treatment options for patients. Validated on the VENTANA PD-L1 (SP263) Assay, the algorithm is ready-to-use and integrated within the Roche uPath enterprise software, a universal digital platform for case management, collabo...
Source: Roche Media News - June 26, 2020 Category: Pharmaceuticals Source Type: news
FDA approves pembrolizumab for cutaneous squamous cell carcinoma
Hematology /Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 24, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Approves Merck ’s Keytruda (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, as monotherapy for the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 24, 2020 Category: Drugs & Pharmacology Source Type: news
Oncotarget: Bacteriome and mycobiome and bacteriome-mycobiome interactions
(Impact Journals LLC) Volume 11 Issue 25 of @Oncotarget reported that the authors aimed to characterize the bacteriome, mycobiome, and mycobiome-bacteriome interactions of oral wash in Head and neck squamous cell carcinoma, or HNSCC, patients and to determine if they are distinct from those of the oral wash of matched non-Head and neck squamous cell carcinoma patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 23, 2020 Category: Cancer & Oncology Source Type: news
Aspergillosis in the Presence of Squamous Cell Carcinoma
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - June 21, 2020 Category: Respiratory Medicine Authors: MeganB Source Type: news
